5 Small Biotech Stocks That Could Get Hotter Than the August Heat презентация

Heat

stock market, on the other hand, is anything but hot right now.

But here are five small biotech stocks that have the potential to bring heat to your portfolio.

Source: MethodShop.com on Flickr

but has yet to post a profit
The biotech has 2 drugs in development – brain cancer vaccine Rintega and cancer drug glembatumumab vedotin (glemba)

to news about Rintega requiring completion of phase 3 study for approval
The stock could easily rebound on positive clinical results for Rintega or glemba

Source: Celldex Therapeutics

in 2015, with shares soaring over 70%
The biotech has four drugs in clinical development, with hepatitis B vaccine HEPLISAV-B getting the most attention

trial got a thumbs-up in July
This is huge because safety concerns derailed FDA approval back in 2013
Shares could rally in anticipation of phase 3 results to be announced in early 2016

Source: Dynavax Technologies Corp.

biotech has two drugs in trials – IMO-8400 targeting B-cell lymphomas and IMO-9200 targeting autoimmune diseases

IMO-8400 in treating Waldenström's macroglobulinemia is scheduled to be released in 4th quarter
Idera will announce target indications for its antisense platform technology later this year

Source: Idera Pharmaceuticals

drugs on the market with its partners – most notably multiple myeloma drug Kyprolis and Promacta, which increases the number of blood platelets

Promacta is expected
With 120 fully-funded programs and 70 partners, there are lots of opportunities for positive news
Partnered cancer drug Evomela expected to launch this year

Source: Ligand Pharmaceuticals

with a market cap of $2.6 billion
The company has three drugs in clinical trials – anticoagulant Betrixiban, FXa inhibitor antidote Andexanet Alfa, and blood cancer drug Cerdulatinib

this year
Andexanet alpha appears to be right on track – with good results from a phase 3 study and a phase 4 confirmatory study rocking along

Source: Portola Pharmaceuticals